HeXun Biosciences Valuation

Is 6986 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6986 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6986 (NT$70.4) is trading below our estimate of fair value (NT$245.03)

Significantly Below Fair Value: 6986 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6986?

Key metric: As 6986 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6986. This is calculated by dividing 6986's market cap by their current earnings.
What is 6986's PE Ratio?
PE Ratio	26.1x
Earnings	NT$124.21m
Market Cap	NT$3.24b

6986 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.7x
Enterprise Value/EBITDA	22.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6986's PE Ratio compare to its peers?

The above table shows the PE ratio for 6986 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.5x
4133 Abnova (Taiwan)	26.5x	n/a	NT$1.7b
6662 BioLASCO Taiwan	21.4x	n/a	NT$909.2m
6848 RBC Bioscience	15x	n/a	NT$258.9m
4747 Johnson Chemical Pharmaceutical Works	39x	n/a	NT$3.2b
6986 HeXun Biosciences	26.1x	n/a	NT$3.2b

Price-To-Earnings vs Peers: 6986 is expensive based on its Price-To-Earnings Ratio (26.1x) compared to the peer average (25.5x).

Price to Earnings Ratio vs Industry

How does 6986's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 6986 is good value based on its Price-To-Earnings Ratio (26.1x) compared to the Asian Life Sciences industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is 6986's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6986 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6986's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

RBC Bioscience

NT$258.9m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.95

-2.2%

32.6%

YungShin Global Holding

NT$14.3b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$53.50

-2.4%

18.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%